Amarin Corp. PLC in 2019 lost in its bid made through a fair trade complaint to curb competition from fish oil supplements for its omega-3-based drug, but it prevailed in stopping supplement firms from linking their fish oil products to the result of its REDUCE-IT (Reduction of Cardiovascular Events Outcomes) trial.
Meanwhile, Scott Gottlieb kept a spotlight on oversight of the consumer health market in his final week as FDA commissioner,...



